Literature DB >> 23223059

Enhancing hematopoietic growth factor performance.

Yen-Michael S Hsu, Daniel C Link.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23223059     DOI： 10.1038/nm.3022

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

Review 1.  Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy.

Authors:  P Mauch; L Constine; J Greenberger; W Knospe; J Sullivan; J L Liesveld; H J Deeg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

2.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.

Authors:  Hal E Broxmeyer; Jonathan Hoggatt; Heather A O'Leary; Charlie Mantel; Brahmananda R Chitteti; Scott Cooper; Steven Messina-Graham; Giao Hangoc; Sherif Farag; Sara L Rohrabaugh; Xuan Ou; Jennifer Speth; Louis M Pelus; Edward F Srour; Timothy B Campbell
Journal:  Nat Med       Date:  2012-11-18       Impact factor: 53.440

3.  Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.

Authors:  A M Lambeir; P Proost; C Durinx; G Bal; K Senten; K Augustyns; S Scharpé; J Van Damme; I De Meester
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

4.  Modulation of hematopoietic stem cell homing and engraftment by CD26.

Authors:  Kent W Christopherson; Giao Hangoc; Charlie R Mantel; Hal E Broxmeyer
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

5.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor.

Authors:  H Wu; X Liu; R Jaenisch; H F Lodish
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

Review 6.  Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

Authors:  Bo Ahrén
Journal:  Expert Opin Emerg Drugs       Date:  2008-12       Impact factor: 4.191

7.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Michael Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Dirk Rades; David P Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Mitchell Machtay; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

Review 8.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

9.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.

Authors:  G J Lieschke; D Grail; G Hodgson; D Metcalf; E Stanley; C Cheers; K J Fowler; S Basu; Y F Zhan; A R Dunn
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

10.  Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.

Authors:  F J de Sauvage; K Carver-Moore; S M Luoh; A Ryan; M Dowd; D L Eaton; M W Moore
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307
  10 in total
  1 in total

1.  Recruitment of circulating breast cancer cells is stimulated by radiotherapy.

Authors:  Marta Vilalta; Marjan Rafat; Amato J Giaccia; Edward E Graves
Journal:  Cell Rep       Date:  2014-07-10       Impact factor: 9.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.